糖尿病设备制造商Beta Bionics申请1亿美元IPO

Beta Bionics (BBNX), a maker of insulin delivery devices, has filed for a $100M initial public offering.  

While Beta Bionics (BBNX) didn't specify terms in its SEC filing, it indicated in a filing fee schedule that it was looking to raise around $100M, a number that is likely a placeholder and subject to change.  

Beta Bionics (BBNX) hopes to list its shares on Nasdaq under the symbol BBNX. Lead bookrunners on the deal include BofA Securities, Piper Sandler and Leerink Partners.  

Based in Irvine, Calif., Beta Bionics' (BBNX) lead product is an insulin delivery device called iLet Bionic Pancreas that utilizes adaptive closed-loop algorithms to autonomously determine insulin doses without requiring a user to count carbohydrate intake. 

The product has been approved by the FDA for the treatment of type 1 diabetes. Beta Bionics (BBNX) hopes to develop the product for the type 2 diabetes market as well. 

Other leading developers of insulin pumps include Tandem Diabetes Care (TNDM), Insulet (PODD) and Medtronic (MDT).